1. Background {#s0005}
=============

Pneumonia remains a leading cause of hospital admissions and is associated with substantial morbidity, mortality, healthcare costs, and days of work lost. ([@bb0230]) Community-acquired pneumonia (CAP) is estimated to cause \~1.5 million hospitalizations and \~100,000 deaths in the US each year, ([@bb0165]) equating to an aggregate cost of nearly \$9.5 billion for 960,000 hospital stays. ([@bb0200]; [@bb0205]) Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), is the most common healthcare-associated infection. ([@bb0135]) Despite clinical advances, the burden of pneumonia on the healthcare system continues to increase, with hospitalization rates for pneumonia increasing by 35% due to *Klebsiella* spp., 23% due to *Pseudomonas* spp., and 23% due to *Staphylococcus aureus* between 2001 and 2011. ([@bb0225]) An aging population, ([@bb0130]) poor sensitivity diagnostic tools, ([@bb0065]; [@bb0020]; [@bb0105]) prolonged courses of empirical antibiotics, ([@bb0080]) and the emergence of antimicrobial resistance([@bb0030]) are all contributing to the persistent and increasing burden of pneumonia.

A hospitalized patient with suspected pneumonia is generally treated empirically. Empirical treatment recommendations in CAP, HAP, and VAP guidelines are based on risk factors for the specific pathogens seen in each form of pneumonia and are consistently associated with overtreatment. ([@bb0015]; [@bb0125]; [@bb0060]) Empirical treatment of CAP includes coverage of atypical but uncommon organisms, ([@bb0010]) and empirical antibiotic decisions are even more difficult for HAP/VAP due to other common antibiotic-resistant pathogens. Moreover, empirical treatment of both CAP and HAP/VAP focuses on MRSA and *Pseudomonas* coverage. ([@bb0115]) Subsequent tailoring of antibiotics is recommended to treat the specific etiology depending on the microbiological diagnosis; ([@bb0155]) however, the turnaround time for a final respiratory culture result can be upwards of 72 hours, during which time patients continue to receive empirical antibiotics. In addition, respiratory cultures are often negative due to their relatively poor sensitivity, particularly when obtained after initiation of antibiotic therapy, and can miss important pathogens when concealed by the growth of multiple organisms in culture. ([@bb0065]; [@bb0020]; [@bb0105])

These limitations of respiratory microbiological culture make effective antibiotic stewardship, defined as "coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration", difficult. ([@bb0025]) As of September 2019, the Centers for Medicare and Medicaid Services now require US hospitals to implement antibiotic stewardship programs, highlighting the need for more appropriate antibiotic use. Antibiotic stewardship aims to minimize broad antibiotic use, which is associated with longer lengths of hospital stay, higher morbidity and mortality, higher hospital costs, nephrotoxicity, and nosocomial infections. ([@bb0075]; [@bb0110]; [@bb0215]) Guideline-driven empirical therapy for pneumonia with broad-spectrum antibiotics and the lag time to definitive microbiological diagnosis mean that (i) de-escalation cannot be performed quickly, making the use of inappropriate antibiotics more likely; and (ii) the prolonged use of broad-spectrum antibiotics promotes the development of antimicrobial resistance. ([@bb0085]; [@bb0070]; [@bb0120]) Therefore, an urgent need exists for the rapid detection of the causative pathogen in pneumonia in order to tailor antibiotics and encourage appropriate antibiotic stewardship.

Rapid diagnostic tests (RDTs) that reduce diagnostic turnaround times from days to hours can address some of the aforementioned clinical challenges. The 2019 Infectious Diseases Society of America CAP guidelines acknowledged the need for rapid, cost-effective, accurate tests to improve directed antibiotic therapy. ([@bb0140]) This crisis has led to a recommendation that antimicrobial prescriptions in high-income countries should be made only when supported by rapid diagnostic evidence, where such tests are available. ([@bb0145]) However, the majority of current RDTs for pneumonia only detect a single organism, ([@bb0210]) and experiences with high-sensitivity RDTs developed for malaria and tuberculosis in resource-poor settings have given rise to concerns that false positive results may result in overtreatment. ([@bb0170]; [@bb0100]; [@bb0220]) However, data on the clinical application and impact of a new generation of highly multiplexed RDTs, which detect multiple organisms in a single respiratory sample by molecular testing, are lacking.

The Unyvero Lower Respiratory Tract (LRT) Panel is an RDT that uses multiplex polymerase chain reaction (PCR) to identify 20 causative agents of severe lower respiratory tract infections (LRTIs) and ten antibiotic resistance determinants in clinical specimens. Targets comprise two Gram-positive bacteria (*Staphylococcus aureus* and *Streptococcus pneumoniae*), 14 Gram-negative bacteria (including *Pseudomonas aeruginosa*), three atypical pneumonia species (*Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia pneumoniae*), and one fungus (*Pneumocystis jirovecii*). The test uses an automated sample-to-answer platform with minimal hands-on time and takes approximately five hours, so it has the potential for use as a point-of-care test.

Using patients enrolled at two of the clinical sites for [NCT01922024](NCT01922024){#ir0005}, a large non-interventional multicenter study that determined the operating characteristics of the Unyvero LRT Panel, we predicted the impact of Unyvero LRT Panel RDT results on adjustment of empiric antibiotic regimens in hospitalized patients with suspected pneumonia.

2. Methods {#s0010}
==========

2.1. Study population, inclusion criteria, and ethical approval {#s0015}
---------------------------------------------------------------

This retrospective study analyzed subjects enrolled in [NCT01922024](NCT01922024){#ir0010} at Northwestern Memorial Hospital (NMH) in Chicago, IL and Beaumont Health (BH; comprising three hospitals in Royal Oak, Troy, and Grosse Pointe) in Michigan. [NCT01922024](NCT01922024){#ir0015} was a large non-interventional multicenter study conducted in 2015--2016 to determine the operating characteristics of the Unyvero LRT Panel. Any study subject enrolled in [NCT01922024](NCT01922024){#ir0020} with an available study ID linked to the electronic medical records (EMR) of NMH or BH was considered for inclusion. Inclusion criteria were hospitalized patients ≥18 years old; with a suspicion of a LRTI; and with an available surplus of \>1 ml endotracheal aspirate (ETA) or bronchoalveolar lavage (BAL) fluid. Exclusion criteria were known infection with HIV, HBV, or tuberculosis. The Northwestern University and Beaumont Health Institutional Review Boards approved retrospective chart review of clinical parameters and outcomes prior to local study site closure (IRB reference number(s) STU00206068 and IORG00000367, FWA 00002516. The date of hospital admission to discharge; date and time of antibiotic administration; culture results from blood, urine, and sites other than respiratory; other microbiologic tests; and discharge disposition were retrieved from the EMR.

2.2. Unyvero LRT panel {#s0020}
----------------------

The Unyvero LRT Panel is an RDT specifically designed for the detection of LRTIs. Specimens were processed with the Unyvero LRT Panel assay as per the manufacturer\'s instructions and as described previously. ([@bb0150]; [@bb0090]) Organisms detected in the assay are shown in [Table 1](#t0005){ref-type="table"} .Table 1The microorganisms and resistance markers detected by the Unyvero LRT Panel.Table 1OrganismResistanceGene*Acinetobacter* spp.[a](#tf0005){ref-type="table-fn"}Carbapenem*kpc*\
*ndm*\
*oxa-23*\
*oxa-24*\
*oxa-48*\
*oxa-58*\
*vimChlamydia pneumoniaeCitrobacter freundiiEnterobacter cloacae* complex^b^*Escherichia coliHaemophilus influenzaeKlebsiella oxytocaKlebsiella pneumoniae*^c^*Klebsiella variicola*3rd generation cephalosporins*ctx-MLegionella pneumophilaMoraxella catarrhalisMorganella morganiiMycoplasma pneumoniaePneumocystis jirovecii*Oxacillin/cefoxitin*mecAProteus* spp.^d^*Pseudomonas aeruginosaSerratia marcescensStaphylococcus aureus*Penicillin*temStenotrophomonas maltophiliaStreptococcus pneumoniae*[^1]

2.3. Definition of concordance and discordance of RDT and culture results {#s0025}
-------------------------------------------------------------------------

Results of the LRT Panel were compared to the final culture results in order to more accurately mimic clinical practice. A sample was defined as concordant if it was: (i) LRT Panel negative, culture negative; (ii) LRT Panel positive, culture positive for the same organism; (iii) LRT Panel positive, culture positive for the same organism and a non-panel organism; or (iv) LRT panel negative, culture positive for a non-panel organism. A sample was defined as discordant if it was: (i) LRT Panel positive, culture negative; (ii) LRT Panel positive, culture positive for a different panel organism; or (iii) LRT Panel negative, culture positive for a panel organism. A sample was defined as both concordant and discordant if the LRT Panel and culture results had the same organism plus an additional panel organism reported by either assay.

2.4. Assessment of predicted changes to empirical antibiotic administration {#s0030}
---------------------------------------------------------------------------

Our assessment of the potential changes to empirical antibiotics based on LRT Panel results assumed that pneumonia was the most likely source of infection. Appropriate versus inappropriate antibiotic regimens were based on the published guidelines for definitive treatment of CAP and HAP ([Fig. 1](#f0005){ref-type="fig"} ) and the organisms detected by the LRT Panel. ([@bb0115]; [@bb0140]) In this study, we did not use resistance markers to guide de-escalation of antibiotic therapy with the exception of *mec*A for *S. aureus*, since *mec*A is the central determinant of MRSA. ([@bb0190]) However, we did use detection of a carbapenemase gene to suggest the need to escalate antibiotic therapy. If MRSA or *P. aeruginosa* were not detected by the panel, then anti-MRSA and/or anti-pseudomonal therapy were deemed unnecessary.Fig. 1Selection of appropriate antibiotic regimen based on published guidelines.Fig. 1

Predicted changes in therapy based on the LRT panel results were defined as: (1) *No antibiotic change indicated*, where an appropriate antibiotic regimen was used to treat the organism identified by the LRT Panel OR no pathogen was identified by LRT Panel and no anti-MRSA or anti-pseudomonal therapy was administered; (2) *Favors de-escalation*, where antibiotics could have been narrowed earlier based on the LRT Panel result; this category included cases where the LRT Panel result was negative but patients were on anti-MRSA and/or anti-pseudomonal therapy; (3) *Favors expansion,* where the antibiotic regimen used would not typically have adequately treated the pathogen identified by the LRT Panel; (4) *De-escalation and expansion favored,* where multiple antibiotics were used and one drug was too broad while the other was too narrow, e.g., LRT Panel reported *P. aeruginosa* but the empirical antibiotic regimen was vancomycin (too broad) and ceftriaxone (too narrow); (5) *Initiate antibiotics,* where antibiotics were not initiated at the time of testing but an organism was identified by the LRT Panel. Results from the LRT Panel were not available to the treating clinician during the study.

2.5. Statistical analysis {#s0035}
-------------------------

Results were analyzed using descriptive statistics. For sensitivity and specificity calculations, routine culture was considered the gold standard. All statistical analyses were performed in SPSS v21 (IBM Statistics Inc., Chicago, IL).

3. Results {#s0040}
==========

3.1. Sample characteristics {#s0045}
---------------------------

Six-hundred and fifty-nine unique samples were enrolled in [NCT01922024](NCT01922024){#ir0025} at the two hospital systems. Study IDs were unavailable for 39 samples, and 5 samples had culture data but no antibiotic use data. Thus, 659 samples were available for determining the assay operating characteristics, 620 samples were available for concordance analysis, and 615 samples for antibiotic change analysis. Three-hundred and ninety-five samples were non-bronchoscopic or bronchoscopic BALs and 225 samples were ETAs obtained from patients in intensive care units and chronic ventilator units of the included hospitals.

3.2. Operating characteristics of the LRT panel and concordance between RDT and culture results {#s0050}
-----------------------------------------------------------------------------------------------

Compared to the bacterial culture standard, the sensitivity, specificity, positive predictive value, and negative predictive value of the Unyvero LRT Panel in this patient population are shown in [Table 2](#t0010){ref-type="table"} . While the sensitivity varied for different organisms, the specificity was uniformly high (96.5--99.5%). The overall sensitivity of the Unyvero LRT Panel was 85.7% (95% CI 82.3--88.7) and the overall specificity was 98.4% (95% CI 98.2--98.7). Accordingly, the assay had a very high negative predictive value of 97.9% (95% CI 97.6--98.1). This compared favorably to a 91.4% sensitivity and 99.5% specificity for pathogen detection in the original nine-center study ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0030}: [NCT01922024](NCT01922024){#ir0035}), which determined operating characteristics using culture plus an independent PCR test as the gold standard for common pathogens, rather than culture alone.Table 2The operating characteristics of the Unyvero LRT panel.Table 2OrganismTPFNFPTNSensitivitySpecificityPPVNPV*Acinetobacter* spp.2321462092.0 (74.0--00.0)97.8 (96.3--98.8)62.2 (49.1--73.6)97.6 (96.0--98.6)*Citrobacter freundii*0166520 (0--97.5)99.0 (98.0--99.7)N/A99.9 (99.9--99.9)*Enterobacter cloacae* complex296362182.9 (66.4--93.4)99.5 (98.6--99.9)90.6 (75.6--96.8)98.6 (97.4--99.4)*Escherichia coli*3831560392.7 (80.0--98.5)97.6 (96.0--98.6)71.7 (60.4--80.8)97.3 (95.7--98.4)*Haemophilus influenzae*1041063571.4 (41.9--91.6)98.5 (97.2--99.3)50.0 (33.2--66.8)97.9 (96.5--98.8)*Klebsiella oxytoca*1651162776.2 (52.8--91.8)98.3 (96.9--99.1)59.3 (43.6--73.3)97.6 (96.1--98.6)*Klebsiella pneumoniae*35121060274.5 (59.7--86.0)98.4 (97.0--99.2)77.8 (64.9--86.9)98.1 (96.9--98.8)*Klebsiella variicola*104654100 (2.5--100)99.4 (98.5--99.8)20.0 (8.6--39.9)100 (100--100)*Moraxella catarrhalis*607646100 (54.1--100)98.9 (97.8--99.6)46.2 (29.1--64.2)100 (100--100)*Morganella morganii*104654100 (2.5--100)99.4 (98.5--99.8)20.0 (8.6--39.9)100 (100--100)*Proteus* spp.1931262586.4 (65.1--97.1)98.1 (96.7--99.0)61.3 (46.9--74.0)97.7 (96.3--98.7)*Pseudomonas aeruginosa*7291656288.9 (80.0--94.8)97.2 (95.5--98.4)81.8 (73.4--88.0)98.4 (97.1--99.1)*Serratia marcescens*144463777.8 (52.4--93.6)99.4 (98.4--99.8)77.8 (56.1--90.6)99.4 (98.5--99.7)*Staphylococcus aureus*109171751686.5 (79.3--91.9)96.8 (94.9--98.1)86.5 (80.0--91.1)96.8 (95.1--97.9)*Stenotrophomonas maltophilia*3412260297.1 (85.1--99.9)96.5 (94.7--97.8)60.7 (50.5--70.1)99.8 (98.9--100.0)*Streptococcus pneumoniae*72364777.8 (40.0--97.2)99.5 (98.7--99.9)70.0 (41.7--88.4)99.7 (99.0--99.9)**Overall41469158990385.7 (82.3--88.7)98.4 (98.2--98.7)72.4 (69.1--99.4)97.9 (97.6--98.1)**[^2]

The concordance between the Unyvero LRT Panel and culture results is reported in [Table 3](#t0015){ref-type="table"} . According to our criteria, 75.0% of results were concordant, 9.2% were discordant, and 15.8% were both concordant and discordant. Of the discordant results, \~4% each were due to either LRT Panel negative/culture positive discordance or vice versa, suggesting that the LRT panel and culture misclassified similar numbers of cases for the major organisms responsible for LRTIs.Table 3Concordance between LRT Panel and culture results.Table 3LRT panel and culture agreementTotal%**CONCORDANT46575.0**LRT negative, Culture negative20332.7LRT positive, Culture positive21134.0LRT positive, Culture positive + Culture positive for non-panel organism345.5LRT negative, Culture positive for non-panel organism172.7**DISCORDANT579.2**LRT negative, Culture positive for panel organism233.7LRT positive, Culture negative254.0LRT positive, Culture negative for panel organism, Culture positive for non-panel organism30.5LRT and culture identifying different panel organisms61.0**BOTH CONCORDANT and DISCORDANT9815.8**Due to additional LRT organism6310.2Due to additional LRT organism, Culture positive for non-panel organism71.1Due to additional culture organism on panel193.0LRT and culture identifying same and different organisms91.5

3.3. Predicted changes to antibiotic therapy based on RDT testing {#s0055}
-----------------------------------------------------------------

Having determined the organism and *mecA* status by the LRT Panel, we next predicted changes to antibiotic regimens based on the published guidelines for treatment of CAP and HAP ([Fig. 1](#f0005){ref-type="fig"}). ([@bb0115]; [@bb0140]) Reassured by the excellent negative predictive value of the LRT panel, we determined that if MRSA or *P. aeruginosa* were not detected by the panel, then anti-MRSA and/or anti-pseudomonal therapies were not indicated.

The predicted changes to antibiotic therapy based on the LRT Panel are shown in [Table 4](#t0020){ref-type="table"} . The LRT Panel result predicted no change in antibiotics in only 12.4% of cases, while in 65.9% (405/615) of patients the LRT Panel results favored de-escalation. Of these, 278/405 (69%) had unnecessary MRSA coverage and 259/405 (64%) had unnecessary *P. aeruginosa* coverage. In the favors de-escalation group, 25.2% (102/405) had a prior positive culture requiring either vancomycin or an anti-pseudomonal antibiotic or a simultaneous extra-pulmonary infection that would have been reasonable to treat with broad empirical therapy. In the favors expansion group, the most common organisms not initially covered by the empirical antibiotic regimen were *Acinetobacter* (n = 17), *Pneumocystis jirovecii* (n = 15), *S. maltophilia* (n = 47), *P. aeruginosa* (n = 18), and MRSA (n = 15).Table 4Predicted changes to antibiotic therapy based on the LRT Panel results.Table 4Potential impact on therapy based on Unyvero LRT results aloneTotalNo antibiotic change indicated76 (12.4%)Favors de-escalation (antibiotics could have been narrowed)405 (65.9%)Favors expansion (antibiotics could have been broadened)67 (10.0%)Favors both de-escalation and expansion of antibiotics48 (7.8%)Start antibiotics19 (3.1%)**Total Samples Available for Analysis615 (100%)**

When considering which RDT-based antibiotic decisions would have resulted in inappropriately narrow therapy, the LRT Panel did not detect a panel (n = 67) or non-panel organism (n = 79) detected by culture in 120 cases ([Table 5](#t0025){ref-type="table"} ). Of the panel organisms, a total of 9 missed *P. aeruginosa* and 18 missed *S. aureus* (13 MSSA, 5 MRSA) may have led to inappropriate narrowing of empirical therapy in 4.3% (27/620) of patients. Conversely, the LRT Panel detected 148 organisms not detected by culture, including 15 *S. aureus* and 12 *P. aeruginosa,* which may have prevented a similar number of inappropriate antibiotic de-escalations based on culture results. The LRT also detected a large number of other pathogens missed by culture that would have required specific treatments, including *Acinetobacter* (11 cases), *S. maltophilia* (19 cases), and *P. jirovecii* (13 cases). Escalation of therapy based on LRT-detected Gram-negative resistance patterns would be suggested for three carbapenem-resistant *P. aeruginosa*, one carbapenem-resistant *E. coli*, nine carbapenem-resistant *Acinetobacter*, and two carbapenem-resistant *K. pneumoniae* cases*.* Table 5Concordance between Unyvero LRT Panel and culture results by organism.Table 5Panel organismConcordantMissed by cultureMissed by LRT panel*Acinetobacter* spp.22111*Chlamydia pneumoniae*000*Citrobacter freundii*061*Enterobacter cloacae* complex2825*Escherichia coli*34123*Haemophilus influenzae*593*Klebsiella oxytoca*1485*Klebsiella pneumoniae*301010*Klebsiella variicola*320*Legionella pneumophila*211*Moraxella catarrhalis*660*Morganella morganii*140*Mycoplasma pneumoniae*220*Pneumocystis jirovecii*3131*Proteus* spp.1993*Pseudomonas aeruginosa*63129*Serratia marcescens*844*Staphylococcus aureus*981518*Stenotrophomonas maltophilia*35191*Streptococcus pneumoniae*632**Total37914867**

Of the non-panel organisms found on culture ([Table 6](#t0030){ref-type="table"} ), 56% (46/79) were common oropharyngeal colonizing organisms that generally do not necessitate antibiotic escalation, and a further 28% (22/79) were organisms that would have been covered even with empirical treatment that removed MRSA and *Pseudomonas* coverage.Table 6Non-panel organisms detected by culture. Organisms with an \* are considered oropharyngeal flora and are not routinely treated with antibiotics when identified on culture.Table 6OrganismNumber (%)*Viridans Streptococcus\**15 (19.0%)*Corynebacterium\**13 (16.5%)*Enterobacter aerogenes*10 (12.6%)*Coagulase negative Staphylococcus\**7 (8.9%)*Citrobacter koseri*5 (6.3%)*Alcaligenes*4 (5.1%)*Enterococcus* spp.\*2 (2.5%)*Prevotella\**1 (1.3%)*Pantoea*1 (1.3%)*Enterobacter sakazakii*1 (1.3%)Group F *Streptococcus\**1 (1.3%)Group C *Streptococcus\**1 (1.3%)*Moraxella/Psychrobacter*1 (1.3%)*Pseudomonas putida*1 (1.3%)*Pseudomonas fluorescens*1 (1.3%)*Enterobacter gergoviae*1 (1.3%)*Aeromonas*1 (1.3%)*Eikenella corrodens*1 (1.3%)*Providencia*1 (1.3%)*Enterobacter amnigenus*1 (1.3%)*Streptococcus mitis\**1 (1.3%)*Beta hemolytic Streptococcus\**1 (1.3%)*Raoultella* spp.1 (1.3%)*Aspergillus*1 (1.3%)*Actinomyces\**1 (1.3%)*Streptococcus agalactiae*1 (1.3%)*Burkholderia cepacia*1 (1.3%)*Lactobacillus* spp.\*1 (1.3%)*Citrobacter youngae*1 (1.3%)*Enterococcus faecium*1 (1.3%)**Total non-panel organisms79**

4. Discussion {#s0060}
=============

The laboratory diagnosis of LRTIs is predominantly based on microbiological cultures, introducing delays and the prolonged use of empirical, broad-spectrum antibiotic therapy in large numbers of patients. Antibiotic resistance is a severe and increasing problem worldwide, mandating the increased use of improved RDTs to reduce antibiotic administration and increase the use of specific antimicrobial therapies. ([@bb0005]; [@bb0050]) Also, in consideration of the current global COVID-19 pandemic, concerns about secondary bacterial infections in hospitalized COVID-19 patients have given rise to the need for timely and appropriate diagnosis of pneumonia to address the over and under-treatment of patients, enabling healthcare providers to practice better antibiotic stewardship, and helping to limit resistance and the development of super-bugs. ([@bb0095]) Rapid multiplex RDTs may play a critical role in this crisis setting. Rapid molecular techniques such as the Unyvero LRT Panel are a promising tool to help guide appropriate therapy and de-escalation from broad-spectrum antibiotic therapy in patients with suspected pneumonia. ([@bb0210]; [@bb0195]) However, like any new medical technology, their potential clinical impact requires testing in clinical practice, and data on multiplex assays in particular are lacking. Here we analyzed the potential impact on antibiotic use in patients with suspected pneumonia with implementation of the Unyvero LRT Panel using data from a non-interventional study that originally evaluated the operating characteristics of the assay.

The overall sensitivity (85.7%) and specificity (98.4%) of the assay for organism detection in our mixed population of BALF and ETA samples were consistent with previous reports for this (88.8% and 94.9%^33^) and another (90% and 97.4%^33^) FDA-approved multiplex LRTI assay and comparable to the sensitivities and specificities reported for traditional ETA and BAL culture. ([@bb0035]; [@bb0180]) A recent evaluation of the Unyvero LRT Panel in 175 BALF specimens reported a positive percentage agreement of 96.5% and negative percentage agreement of 99.6% with quantitative bacterial culture, ([@bb0055]) and the original prospective nine-center study, which compared the LRT Panel against a composite comparator of culture plus an independent PCR test, reported 91.4% sensitivity and 99.5% specificity for pathogen detection ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0040}: [NCT01922024](NCT01922024){#ir0045}). These discrepancies, particularly in sensitivity, are likely to be dominated by pre-analytical factors and the choice of comparator. For instance, despite ETA samples being recommended for use in the diagnosis of VAP in current guidelines, ([@bb0115]) concordance between cultures from ETA samples and BALF are suboptimal. ([@bb0040]; [@bb0175]) Our population represented a mixed cohort of BALF and ETA samples compared against culture alone without supplementary molecular testing. Nevertheless, and importantly from the perspective of clinical implementation, the assay had a consistently very high negative predictive value of 97.9%. Therefore, the significant number of de-escalations based on a lack of MRSA (278/405, 69%) or *P. aeruginosa* (259/405, 64%) detection by the panel can be made with high degree of clinical confidence. This de-escalation strategy would be particularly advantageous when empirical antibiotics are used to cover organisms on the LRT panel that are difficult to culture including *Legionella*, *Pneumocystis*, *Mycoplasma* and *Chlamydia.*

The LRT Panel results could have changed the choice of antibiotic used in the majority of cases, potentially leading to more effective antibiotic stewardship both in terms of regimen and duration. In 66% of cases, the initial antibiotic regimen was too broad for the pathogen identified by the LRT Panel and subsequent culture, consistent with a recent report in the critical care setting that multiplex PCR for respiratory pathogens would alter the antibiotic choice earlier in \>50% of cases. ([@bb0090]) Contrary to previous concerns that RDTs may lead to over-treatment, ([@bb0170]; [@bb0100]; [@bb0220]) our data suggest that implementation of this RDT would de-escalate antibiotic use in the majority of cases. Even in cases where the LRT Panel result was negative for any organism, initial empirical antibiotic regimens usually still included anti-MRSA and anti-pseudomonal drugs. Conversely, in cases where the organism identified by the LRT panel was missed by culture, the patient was still usually covered by the empirical antibiotic regimen. In this scenario, LRT results may potentially prevent inappropriate de-escalation.

A recent study of the BioFire FilmArray Pneumonia panel concluded that the panel could also allow antibiotic adjustment in 71% of cases including discontinuation or de-escalation in 48% of patients. ([@bb0045]) These findings, particularly the utility of a rapid diagnostic test for antibiotic de-escalation, were similar to the findings in our study of the LRT Panel. The two panels have important differences. The LRT Panel includes important etiologic agents of pneumonia like *Stenotrophomonas maltophilia*, *Pneumocystis jirovecii*, *Klebsiella variicola*, *Morganella morganii* and *Citrobacter freundii*; these organisms are not on the FilmArray Pneumonia panel. However, the FilmArray Pneumonia panel includes *Klebsiella aerogenes*, *Streptococcus agalactiae* and *Streptococcus pyogenes*, and common respiratory viruses not on the LRT panel. Another difference between these panels is that the LRT Panel includes ten resistance genes while the FilmArray Pneumonia Panel includes only six. The FilmArray Pneumonia Panel provides semi-quantitative results using four different bin categories corresponding to 10^4^, 10^5^, 10^6^, or ≥10^7^ copies/mL while the LRT Panel does not. Correlations to quantitative culture results reported as CFU/mL are however difficult, and agreement rates may be variable between organisms and in different specimen types; and concordance may be low, especially at lower CFU/mL densities. ([@bb0160]) The role of reporting semi-quantitative PCR results has yet to be defined in clinical practice.

Our evaluations regarding antibiotic escalation and de-escalation were based on the assumption that pneumonia was the most likely source of infection, as the study had enrolled only patients with a suspected LRTIs. In practice, in cases where another positive culture or extra-pulmonary infection is documented, the LRT Panel result should be used in conjunction with the other culture results to make decisions on therapy. If pneumonia is the only suspected site of infection, treatment could be narrowed and/or combination therapy discontinued, with important antibiotic stewardship implications. However, in patients presenting with sepsis or septic shock of unclear etiology, antibiotic decisions should not be based solely on an RDT.

This study has a number of limitations. We constructed a hypothetical estimate of the utility of the test, assuming 100% compliance with the assay and its results, which is unlikely to be achievable in practice. The decision to alter antimicrobial therapy was based on clinical guidelines, so mainly exploited results from two of the 20 organism targets and only two resistance markers, *mecA* and carbapenemase enzymes; it is possible that the negative predictive value for the detection of phenotypic resistance could be lower depending on prevalence of non-panel resistance mechanisms. ([@bb0185]) Whether these potential false-negative and false-positive molecular results will degrade the utility of the assay awaits a prospective interventional study performed at multiple sites. The exclusion of expectorated sputum from the analysis may also have increased the specificity of the test for pathogens causing true disease.

4.1. Interpretation {#s0065}
-------------------

Application of this multiplexed LRTI rapid diagnostic test would most commonly predict adjustment to antibiotic prescribing for patients in whom MRSA or *P. aeruginosa* were unlikely to be the causative organism. Given the consistently high negative predictive value of the RDT and that *mec*A is the central determinant of MRSA, ([@bb0190]) even with the caveats of this study, our findings suggest that implementation of a multiplexed LRTI RDT is likely to alter the antibiotic management of significant numbers patients presenting with suspected pneumonia. When coupled with antimicrobial stewardship programs, rapid tests that identify organisms in respiratory samples can optimize antimicrobial utilization and patient outcomes.
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[^1]: *Acinetobacter* spp. detected by LRT panel: *A. baumannii*, *A. calcoaceticus*, *A. haemolyticus*, *A. junii*, *A. lwoffii*, *A. nosocomialis*, *A. parvus*, *A. pittii*. ^b^*Enterobacter cloacae* complex includes: *E. asburiae*, *E. chengduensis*, *E. chuandaensis*, *E. cloacae*, *E. hormaechei* (incl. Ssp. *xiangfangensis*), E. *kobei*, *E. ludwigii*, E. roggenkampii, *E. sichuanensis* as well as *E. bugandensis* (not yet recognized as member of the *E. cloacae* complex). ^c^*Klebsiella pneumoniae* includes two variants: *K. pneumoniae* (variant 1), and *K. quasipneumoniae* (variant 2). ^d^*Proteus* spp. includes *P. cibarius*, *P. hauseri*, *P. mirabilis*, *P. penneri*, and *P. vulgaris*.

[^2]: **Abbreviations:** TP, true positive; FN, false negative; FP, false positive; TN, true negative; PPV, positive predictive value; NPV, negative predictive value.
